Financial Gravity Companies Inc. Invests $166,000 in Cambrex Co. (CBM) Stock
Financial Gravity Companies Inc. acquired a new stake in shares of Cambrex Co. (NYSE:CBM) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 2,939 shares of the biotechnology company’s stock, valued at approximately $166,000.
A number of other large investors also recently modified their holdings of the business. Stifel Financial Corp raised its stake in shares of Cambrex by 0.8% during the 2nd quarter. Stifel Financial Corp now owns 4,580 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 37 shares during the period. State Street Corp raised its stake in shares of Cambrex by 5.1% during the 2nd quarter. State Street Corp now owns 779,820 shares of the biotechnology company’s stock worth $46,600,000 after purchasing an additional 37,669 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Cambrex by 1.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 25,099 shares of the biotechnology company’s stock worth $1,500,000 after purchasing an additional 321 shares during the period. Crossmark Global Holdings Inc. bought a new stake in shares of Cambrex during the 3rd quarter worth $354,000. Finally, State Board of Administration of Florida Retirement System raised its stake in shares of Cambrex by 44.7% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 49,594 shares of the biotechnology company’s stock worth $2,728,000 after purchasing an additional 15,309 shares during the period.
A number of equities research analysts have recently commented on CBM shares. William Blair started coverage on Cambrex in a research note on Tuesday, January 16th. They set an “outperform” rating on the stock. Zacks Investment Research upgraded Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday, January 15th. Finally, Longbow Research cut Cambrex from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. Cambrex has an average rating of “Hold” and an average target price of $60.00.
Cambrex (NYSE:CBM) last released its earnings results on Thursday, February 8th. The biotechnology company reported $1.27 EPS for the quarter, topping the Zacks’ consensus estimate of $1.10 by $0.17. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The company had revenue of $182.28 million for the quarter, compared to analysts’ expectations of $181.39 million. During the same period in the previous year, the business posted $1.23 EPS. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. equities analysts expect that Cambrex Co. will post 2.76 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Financial Gravity Companies Inc. Invests $166,000 in Cambrex Co. (CBM) Stock” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/03/03/financial-gravity-companies-inc-invests-166000-in-cambrex-co-cbm-stock.html.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.